A second administration of one half J1 A C enflurane for two hours one week following a previous identical exposure caused no increase in urinary inorganic Fluoride excretion (Up V).
fluoride concentrations are usually below the nephrotoxic threshold, however values in the toxic range have been measured (:\Iaduska 1974, Cousins, :VIazze and Greenstein 1976) . Enzyme induction by phenobarbitone increases methoxyflurane metabolism and causes a similar increase in renal toxicity . Also, inhalation agents are capable of inducing their own metabolism (Van Dyke 1966) . This raises the question; does enflurane metabolism to inorganic fluoride increase with a second exposure, and if so is this sufficient to cause nephrotoxicity?
The present study examines urinary inorganic fluoride excretion following administration of a second identical dose of enflurane at seven days after a first dose. "
METHODS

Subjects
Eight healthy subjects, mean age ~2 (four males and four females) volunteered for the study. All had normal history and physical examination. SUbjects were screened to rule out abnormalities in kidne\' or liver function; those on chronic drug therapy of any nature were excluded from the study. Subjects were asked to abstain from alcohol intake during the period of the study.
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Drug Administration
An identical sub-anaesthetic dose of enflurane was administered on two occasions at seven day intervals. Prior to each dose of enflurane no food or fluid intake was allowed for tw'elve hours. Enflurane was administered from an Enfluratec* which had been calibrated by gas chromatography.
In the supine position, subjects initially breathed 100% oxygen at a flow rate of 7 Ljmin for three minutes via a tightly fitting face mask and a non-rebreathing circuit. Enflurane was then introduced at a concentration sufficient to maintain blood concentration equivalent to approximately one half MAct (0,8%) (Gion and Saidman 1971) for precisely two hours.
Enflurane dose was calculated by multiplying anaesthesia time by the mean blood level expressed as a fraction of MAC., i.e. MAC HOURS. (Cousins and Mazze 1973) i.e., two hours X one half MAC =1 MAC hour. Enflurane concentration at the mask was checked at half hourly intervals by means of a stop-cock attachment on the side of the mask. Arterial blood enflurane concentration was also measured at approximately half-hourly intervals. All anaesthetic concentrations were determined by gas chromatography.
Blood gas de terminations were also carried out during maintenance of anaesthesia. Blood pressure and pulse rate were monitored at frequent intervals.
LABORATORY INVESTIGATIOXS
Prior to each dose of enflurane (day 1 and day 8), measurements were made of serum sodium, potassium, uric acid, creatinine urea nitrogen, calcium, alkaline phosphatase, 'serum glutamic oxalo-acetic transaminase, serum glutamic pyruvic transaminase, and lactic acid dehydrogenase. Twenty-four hour urine volume was determined and measurements were made of urine concentration of inorganic fluoride (Tusl 1972 ) and creatinine. Twenty-four hour urinary inorganic fluoride and creatinine excretions and clearances were calculated. Urine specimens were obtained on the day prior to each enflurane exposure and on the first two days following exposure (days 3 and 4 and days 10 and 11). Serum specimens were obtained on the day prior to the first dose of enflurane * Cyprane Ltd., Keighley, Yorkshire.
t MAC: Minimum al!'aesthetic concentration necessary to prevent movement III response to surgical stimulation in 50% of patients.
(day 1) and for two days following the last dose of ~nflurane (day 10 and 11). However, in one patlent where abnormalities were detected serum determinations were repeated untii normal. Full blood count and oral temperatures were determined after each exposure. Serum and urine determinations were as described above.
STATISTICAL METHODS
For each subject results for each variable obtained during days 1-4 of the first exposure were compared to days 8-11 of the second exposure. Pre to post exposure differences were also calculated for each variable. The pre to post exposure difference obtained at the first eXI;>0sure was compared to the second exposure. PaIred t tests were used for all comparisons.
RESULTS
Prior to the first exposure there were no abnormalities in serum or urine variables. Subjects' age, weight and sex are shown in Table 1 . During ~he entire period of the study, complete 24 hour unne samples were obtained as indicated by the constancy of calculated creatinine excretion (Table 2) .
During enflurane administration, blood pressure and pulse rate were not significantly changed and blood gas measurements showed no evidence of hypercarbia or hypoxia. Measurements of enflurane concentration in the blood were not significantly different on the se~ond exposure compared to the first (Table 3) . Pnor to the second exposure, on day 8, urinary fluoride excretion was increased above normal limits only in subject ;) (Table 4) . This difference persisted following exposure (day lO-II compared to day 3-4). However, there \\'ere no significant differences between pre to post exposure deltas for the first exposure compared to the second. Because of the small number of subjects studied, comparisons were 
. , two days after her second exposure (serum glutamic oxalo·acetic transaminase 60 mll.'/ml, serum glutamic pyruvic transaminase 85 mIC rnl, and lactic acid dehydrogenase 285 mlLml, alkaline phosphatase 100 mIC/m!.). Thest variables had returned to normal one \veek later. There were no abnormalities in blood count. 1'yrexia did not occur after any of the anaesthesia exposures.
DISCl'SSIOX This study extends previous information which was limited to the metabolism of single doses of enflurane in man (Chase et al. 1971 , :\laduska 1974 , Cousins, :\Iazze and Greenstein 1976 . Repeated subanaesthetic doses of enflurane at one \\'eek interval did not increa~e urinary inorganic fluoride excretion (C F\')' In general, urinary fluoride excretion had returned to normal seven days following the first exposure. l're to post exposure differences indicated that the metabolism of enflurane \\'as not increased with the second exposure (Table 4) . Careful cuntrol of time of exposure and enflurane blood level assured that enflurane dose was not significantly different at each exposure (Table 3) . Constancy of creatinine excretion of each subject -during the entire stud\' indicated cOIllplete :2-1 hour urine colkctions. l'rinary fluoride excretion i::; the end result of lIwtabolite production by tIle liver and ab\) uptake b\' tissues other than the liver, such as bOIle. If it is assumed, in this stulh', that tissue uptake did not change bet\\'een the first and ,.;econd exposure, then urinary fluoride excretion can be taken as an indication of cnflurane metabolism. This seems reasonable since cardiorespiratory, liver and renal homeostasis was not changed according to variables measured.
l\.epeat administration of inhalation anaestllt'tics has not been studied in man with precise measurements of metabolism; most information is limited to chronic " occupational" exposure. l'n.>\·ious animal studies of chroll ie inhalation of volatile anaesthetics ha\'(' shown that this causes increased metabolism of other drugs (Berman and Bochantin 1 !l70) and abo metabolism of the anaesthetic per se (\'an Dyke 1 !l66). It has also been shown in animals that chronic inhalation of sub-anaesthetic concentrations of anaesthetics causes an increase in l'\·tochrome 1'--1;')0 reductase (Brown 1!l7 4) . . .\naesthetists who are chronically exposed to low concentrations of various inhalation anaesthetics have been shown to metabolize AI/III'st"l'sia alld [ Exposure I \·s Exposure 2 p(Paired t-test) >0'5 >0'5 >0·5 >0·5 >0·,; (a) Baseline VFV in man drinking fluorinated water ranges from 30-80 fLM day. 'rhus only subject 5 has a value differing from normal variation prior to second exposure. (b) /':, VFV =Mean of first two days post exposure minus the day prior to exposure. (c) /':, VFV is compared on a weight basis since some subjects in the study were considerably he<l-'"ier than others (Table I) .
halothane more rapidly than non-exposed persons (Cascorbi, Blake and Helrich 1970) . However, it is not known what length of exposure is necessary to cause induction and how long induction remains after cessation of exposure. From the present study of repeat exposure, it is clear that exposure more frequently than every c;even days would be required since enflurane dosage was equivalent to usual clinical practice. As in previous studies of fluorinated methylethyl ethers (Cousins et al. 1974, Van Dyke and Wood 1973) , there was a twofold variation in the de fluorination of enflurane ( (Barr et al. 1974) .
The question of induction of enflurane's metabolism by other means, such as phenobarbitone, is of crucial importance in determining enflurane's potential for renal toxicity. In '"<.'ifro studies in an animal model have shown that treatment with phenobarbitone for three days prior to enflurane exposure causes increased enflu:-ane defluorination by isolated liver microsomes (Cousins, unpublished data) . In contrast however, ill 1.'i"o studies in the model have revealed no increase in urinary inorganic fluoride excretion when rats are treated with phenobarbitone prior to enfiurane exposure (Figure 2) . The explanation for this apparent paradox lies in enfiurane's physical characteristics: the low fat solubility of enflurane permits ven' rapid clearance of enflurane from the body following exposure and thus the timl' is very limited during which enfiurane is available to the liver microsomal system in l'ivo. This means that, in 'uivo, substrate (enflurane) is rate limiting rather than the amount of microsomal enzyme. In ('itro enflurane is kept in contact with microsomal enzyme and thus a doubling of the amount of enzyme present (by induction with phenobarbitone) causes a significant increase in enfiurane defiuorination.
It is possible that substrate will also be rate limiting in man since enfiurane is very rapidl~' cleared as has been shown by the sharp decline in metaholite excretion in the present study. If this proves to be so, enzyme induction will not pose an increased risk of nephrotoxicity associated with enfiurane anaesthesia. I t has recently been reported that rates of elimination of several drugs are genetically, rather than environlllentallv controlled in healthy non-medicated suhjects (\' esse I 1970) .
Twin studies of halothane metabolism ill 'i.'il'O confirmed that genetic control was responsible for large individual differences in metabolism (Cascorbi et al. 1971) . 111 ,'itro studies have revealed that human hepatic microsomal activity differs from person to person (Yan Dyke and Wood 1973) . This would imply that, for one individual, drug metabolism would be reproducible provided enzyme induction or inhibition did not occur. The present study provides strong support for this concept. There was excellent reproducibility of blood levels of FI(;l'I{E :!.--Thl' l'ffect of treatment with plll'nobarb on urinary inorganic fluoride excretion (liF V) in Fischer rats. "I n \'i"o ", there is no significant ditterence between l' F \. following cnflurane expo,urL' compared to l' F -\' following pre-treatment with phenobarb and subsequent cnflurane exposure. (Cousins and :\Iazze, unpublishl'" data.) enflurane and enfiurane metabolism for each subject. However, there were large individual variations in enflurane metabolism between subjects (Figure 1 ). Since subjects were the sallle age and drug free, these differences were most likely genetically determined. Previous data from single doses of enfiurane (Cousins, :\Iazze and Greenstein 1976) 
that urinary inorganic fluoride excretion remained elevated for approximately six days following anaesthesia. Thus a repeat exposure within this time interval would be expected to produce higher peak concentrations of inorganic fluoride because of the residual from the previous exposure. This effect would be in addition to any enhancement of defluorination due to enzyme induction. These considerations raised ethical objections to an exposure interval of less than seven days in the present study. However, if enflurane is used in surgical patients at intervals of less than seven days it will be important to ensure close surveillance of renal function and inorganic fluoride concentration in urine and serum.
The conclusions from this study must be limited to the following:
(1) Under the low dosage conditions described; a second exposure did not result III increased inorganic fluoride excretion.
(2) The kidney is capable of excreting the major portion of the inorganic fluoride resulting from a low enflurane dose within one week. With reference to (1), it is possible that, as in animals, (Barr, Cousins, Mazze et al. 1974 ) enzyme induction in vivo does not result in significant increase in enflurane defluorination in man. It is also possible that enflurane defluorination was initially enhanced but this effect was no longer present seven days later. Despite these qualifications, the two conclusions of this study have clinical significance since the dose of enflurane employed was very similar to that commonly used to supplement muscle relaxant/nitrous oxide techniques. Thus a healthy patient would not be expected to be at risk from nephrotoxicity if enflurane is used in this low dosage at one week interval.
